AKRO Logo

Akero Therapeutics, Inc. (AKRO) 

NASDAQ
Market Cap
$2.15B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
63 of 774
Rank in Industry
48 of 432

Largest Insider Buys in Sector

AKRO Stock Price History Chart

AKRO Stock Performance

About Akero Therapeutics, Inc.

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH …

Insider Activity of Akero Therapeutics, Inc.

Over the last 12 months, insiders at Akero Therapeutics, Inc. have bought $3.68M and sold $23.88M worth of Akero Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Akero Therapeutics, Inc. have bought $23.17M and sold $45.65M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Graham G. Walmsley (director) — $11.03M.

The last purchase of 100,000 shares for transaction amount of $1.98M was made by Graham G. Walmsley (director) on 2023‑12‑08.

List of Insider Buy and Sell Transactions, Akero Therapeutics, Inc.

2024-11-15SaleChief Development Officer
9,061
0.0122%
$27.73$251,274+9.08%
2024-11-06SaleChief Development Officer
10,000
0.0143%
$35.19$351,890-8.22%
2024-11-01SalePresident and CEO
108,366
0.1532%
$31.73$3.44M+0.15%
2024-11-01SaleChief Operating Officer
50,716
0.0713%
$31.57$1.6M+0.15%
2024-11-01SaleChief Development Officer
15,485
0.0225%
$32.62$505,105+0.15%
2024-10-30SaleChief Development Officer
4,515
0.0069%
$32.53$146,855+5.31%
2024-10-18SalePresident and CEO
63,539
0.0924%
$31.53$2M+2.11%
2024-10-17SalePresident and CEO
3,103
0.0045%
$31.12$96,559+2.95%
2024-10-16SalePresident and CEO
24,992
0.0382%
$31.14$778,151+1.38%
2024-10-15SaleChief Development Officer
14,825
0.0222%
$30.50$452,233+4.34%
2024-10-14SaleChief Operating Officer
40,000
0.0592%
$30.15$1.21M+3.77%
2024-10-14SaleChief Development Officer
6,136
0.009%
$30.03$184,258+3.77%
2024-10-01SaleChief Operating Officer
10,000
0.0138%
$28.18$281,770+6.90%
2024-09-20SaleChief Development Officer
5,500
0.0078%
$27.65$152,086+9.12%
2024-09-18SaleChief Development Officer
3,871
0.0057%
$27.56$106,685+11.31%
2024-09-17SaleChief Development Officer
2,037
0.003%
$27.55$56,115+12.50%
2024-09-16SaleChief Development Officer
2,485
0.0037%
$27.52$68,375+11.80%
2024-09-10SalePresident and CEO
1,738
0.0025%
$26.18$45,501+14.30%
2024-09-10SaleChief Operating Officer
568
0.0008%
$26.18$14,870+14.30%
2024-09-10SaleChief Scientific Officer
537
0.0008%
$26.18$14,059+14.30%

Insider Historical Profitability

6%
Graham G. Walmsleydirector
800000
1.1461%
$30.8790+9.4%
Apple Tree Partners IV, L.P.10 percent owner
5830203
8.3528%
$30.8720<0.0001%
Versant Venture Capital VI, L.P.10 percent owner
3092698
4.4309%
$30.87122+13.18%
venBio Global Strategic Fund II L.P.10 percent owner
3033552
4.3461%
$30.87125+13.18%
Atlas Venture Fund XI, L.P.10 percent owner
505099
0.7236%
$30.8710+13.18%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Janus Henderson$154.59M8.856.12M+42.16%+$45.85M0.08
RTW Investments, LP$137.21M7.865.43M+51.19%+$46.46M2.06
General Atlantic$132.21M7.575.23M+193.1%+$87.1M3.44
Wellington Management Company$131.69M7.545.21M+80.89%+$58.89M0.02
BlackRock$123.59M7.084.89M+17.03%+$17.99M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.